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Diabetes mellitus is defined as a group of metabolic diseases that are associated with the
presence of a hyperglycemic state due to impairments in insulin release and/or function.
While the development of each form of diabetes (Type 1 or Type 2) drastically differs,
resultant pathologies often overlap. In each diabetic condition, a failure to maintain healthy
muscle is often observed, and is termed diabetic myopathy. This significant, but often
overlooked, complication is believed to contribute to the progression of additional diabetic
complications due to the vital importance of skeletal muscle for our physical and metabolic
well-being. While studies have investigated the link between changes to skeletal muscle
metabolic health following diabetes mellitus onset (particularly Type 2 diabetes mellitus),
few have examined the negative impact of diabetes mellitus on the growth and reparative
capacities of skeletal muscle that often coincides with disease development. Importantly,
evidence is accumulating that the muscle progenitor cell population (particularly the
muscle satellite cell population) is also negatively affected by the diabetic environment,
and as such, likely contributes to the declining skeletal muscle health observed in diabetes
mellitus. In this review, we summarize the current knowledge surrounding the influence
of diabetes mellitus on skeletal muscle growth and repair, with a particular emphasis on
the impact of diabetes mellitus on skeletal muscle progenitor cell populations.
Keywords: diabetes mellitus, muscle satellite cells, PICs, skeletal muscle, muscle regeneration, Type 1 diabetes
mellitus, Type 2 diabetes mellitus
SKELETAL MUSCLE AND MUSCLE PROGENITOR CELLS
Skeletal muscle is capable of adapting to numerous stimuli, with
these responses manifested through changes in muscle size, fiber-
type distribution, and/or metabolism. A critical component in
skeletal muscle maintenance and plasticity is the presence of mus-
cle progenitor cells. A complex network of intrinsic and extrinsic
factors mediate changes to these progenitor cells, with such fac-
tors influenced by, and influential to, skeletal muscle health.
Diseases that negatively impact muscle health, such as diabetes
mellitus, may do so by negatively affecting progenitor cell quan-
tity and/or functionality. As such, these cells (or a sub-population
therein) function as a primary therapeutic target to attenuate
deficits in muscle health with disease progression. While the most
well defined of these progenitor cells is the satellite cell (SC;
Hawke and Garry, 2001; Zammit and Relaix, 2012), evidence of
a number of non-satellite cell progenitor populations contribut-
ing to the maintenance of skeletal muscle in health and disease
has emerged in recent years (Pannérec et al., 2012). Throughout
this brief review we will use the terms “satellite cells” or “SCs”
to define this heterogeneous progenitor cell population, acknowl-
edging that as our understanding of these other unique cell
populations becomes clearer, we may revisit roles once allocated
specifically to the muscle satellite cells.
PATHOPHYSIOLOGY OF TYPE 1 AND 2 DIABETES MELLITUS
The onset of Type 1 diabetes mellitus (T1DM) often occurs
in childhood or adolescence and is characterized by the
immune-mediated destruction of pancreatic β-cells leading to
insulin deficiency. While T1DM accounts for only ∼10% of dia-
betic cases, its prevalence over the past 30 years has increased
worldwide (Onkamo et al., 1999; Gale, 2002). Adolescent muscles
subjected to atrophic stimuli are more likely to endure irreversible
changes (Darr and Schultz, 1989; Mozdziak et al., 2000), thus
the presentation of T1DM during this critical growth period
can detrimentally impact long-term muscle health. In contrast,
Type 2 Diabetes Mellitus (T2DM) accounts for∼90% of diabetes
mellitus cases (Masso-Gonzalez et al., 2009), and is expected to
affect almost 8% of the worldwide population by 2030 (Shaw
et al., 2010). Adverse health behaviors, particularly sedentary
lifestyles and increased adiposity, have lead to a high incidence
of insulin resistance and impaired fasting glucose (American
Diabetes Association, 2006). Without therapeutic intervention,
the insulin-resistant state often precipitates to pancreatic β-cell
death and progression to insulin-dependent T2DM.
While the etiology of T1DM and T2DM are distinct, the end
result is number of common co-morbidities including nephropa-
thy, neuropathy, and cardiovascular disease. Diabetic myopathy,
characterized by reduced physical capacity, strength, and mus-
cle mass (Andersen et al., 1996, 1997, 2004, 2005), is a relatively
understudied complication of diabetes mellitus, but is believed
to directly influence the rate of co-morbidity development. This
is based on the fact that skeletal muscle functions as the largest
site for glucose uptake (DeFronzo et al., 1981), and therefore
changes to skeletal muscle health can impact whole-body glucose
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homeostasis. A vital component to the maintenance of skeletal
muscle is its SC population. As such, changes to SC functional-
ity with diabetes mellitus would impact skeletal muscle health.
Here we review the current state of knowledge on the relation-
ship between skeletal muscle health and diabetes mellitus, with
a particular focus on the fate and function of skeletal muscle
progenitor cell populations.
SKELETAL MUSCLE IN DIABETES MELLITUS
T1DM
Muscle growth and development is significantly impaired in
T1DM, resulting in reduced muscle mass and myofiber size,
poor metabolic control, and a switch to a glycolytic phenotype
(Andersen et al., 1997, 2004; Crowther et al., 2003; Fritzsche
et al., 2008; Krause et al., 2009, 2013). While initial studies
in human T1DM reported no difference in capillary density
(Leinonen et al., 1982), investigations in T1DM mice illustrate
that the disease is associated with a decline in skeletal muscle cap-
illarization and angiogenesis (Kivelä et al., 2006; Krause et al.,
2009). These alterations to muscle structure and metabolism
often are associated with reductions in muscle function, as pre-
viously demonstrated (Huttunen et al., 1984; Poortmans et al.,
1986; Almeida et al., 2008; Gordon et al., 2010). In addition
to growth and function, the capacity for repair from dam-
age is also adversely affected by T1DM, as indicated by studies
of muscle regeneration using chemical and genetic models of
T1DM (Gulati and Swamy, 1991; Talesara and Vashishta, 2000;
Vignaud et al., 2007; Krause et al., 2011, 2013). Collectively,
these studies highlight the negative impact T1DM is having on
skeletal muscle and its potential for growth, maintenance, and
repair.
SATELLITE CELLS AND T1DM
Satellite cells from streptozotocin (STZ)-treated diabetic mice
fail to activate properly, resulting in failed regeneration follow-
ing chemically induced muscle injury (Jeong et al., 2013). This
extreme catabolic state has previously been shown to promote
the fusion of SCs to adjacent muscle fibers in T1DM mice, as
this is thought to promote the release of factors that function to
sustain muscle integrity in this less than favorable metabolic con-
dition (Brannon et al., 1989). Furthermore, Aragno et al. (2004)
reported reduced myogenic regulatory factor expression and
impaired differentiation in T1DM-derived myoblasts. Attenuated
muscle repair has also been observed in T1DM mice (Krause
et al., 2011, 2013). The impaired regeneration with diabetes was
attributed to an elevation in plasma PAI-1 resulting from atten-
uated extracellular matrix (ECM) turnover. The delay in ECM
turnover inhibited macrophage and SC migration into the dam-
aged/necrotic regions of injured muscle. Interestingly, despite
systemic increases in PAI-1, the impaired regeneration occurred
in a muscle-specific pattern (Krause et al., 2013), indicating
that muscles are intrinsically resistant to the T1DM environ-
ment. It is becoming increasingly clear that alterations to muscle
protein turnover cannot, by itself, account for diabetic myopa-
thy. Although studies investigating SCs in T1DM remains lim-
ited, evidence indicates that functionality is affected. Clinically,
it is important to appreciate that T1DM-onset almost always
occurs during childhood/adolescence, a period of extensive mus-
cle growth. Thus, understanding alterations to the SC population
in T1DM is essential for the development of therapeutic strategies
to maximize muscle health during this vulnerable time.
T2DM
Similar to observations in T1DM, skeletal muscle of T2DM sub-
jects exhibit increased glycolytic fiber number (Mårin et al., 1994;
Nyholm et al., 1997), muscle atrophy (Huang et al., 2010), and
decreases in capillary density (Prior et al., 2009). Perturbations
to muscle metabolism in T2DM are common, resulting in
decreased intermyofibrillar mitochondrial content and abnor-
mal lipid deposition (Nielsen et al., 2010; Chomentowski et al.,
2011). As a consequence of these unfavorable changes, the
muscle becomes “metabolically inflexible” as it cannot easily
switch between fat and carbohydrate oxidation in response to
insulin (Kelley and Mandarino, 2000). Functional impairments
are also evident, as demonstrated by a decline in muscle strength
(Andersen et al., 2004; Park et al., 2006), a finding strongly
correlated with intramuscular fat storage (Hilton et al., 2008).
Studies of muscle regeneration in insulin-resistance/T2DM ani-
mal models (Nguyen et al., 2011) further identify attenuated
skeletal muscle plasticity, with deleterious changes to SC func-
tion theorized as a central mechanism underlying the observed
outcomes.
As discussed, diabetes mellitus impinges on skeletal mus-
cle health. Studies have noted that the diabetic environment
enhances protein degradation (Price et al., 1996; Lecker et al.,
1999;Mitch et al., 1999;Mastrocola et al., 2008).While these stud-
ies are well conducted, it was not within their scope to investigate
all components required for skeletal muscle growth and mainte-
nance. Indeed, SCs are indispensable for such events (Zammit
and Relaix, 2012), and thus a more complete understanding
of the impact of the diabetic environment on SC function
is needed.
SATELLITE CELLS AND T2DM
While studies directly assessing SC function with T2DM remain
limited, a number of recent investigations have evaluated SC
behavior with hyperglycemia and/or lipotoxicity. For instance,
3 weeks of a high fat feeding (HFF) affected SC content and
functionality, with the latter classified as the quantity of regen-
erating fibers present following injury (Fitzpatrick et al., 2011).
Hu et al. (2010) demonstrated reduced muscle regeneration after
8-months HFF that was attributed to a delay in myofiber matura-
tion, rather than SC activation or proliferation. In vitro studies
have also shown that SCs incubated in high glucose medium
have an increased propensity to differentiate into adipocytes
(Aguiari et al., 2008), suggesting that SC myogenic capacity may
be impacted by uncontrolled diabetes. This is further substanti-
ated through the use of genetic models of obesity and diabetes.
The Obese Zucker Rat (OZR), a model for the metabolic syn-
drome, displays reduced SC proliferative capacity though quies-
cent SC percentages remain unchanged (Peterson et al., 2008);
findings consistent with observed alterations to Akt signaling and
myogenic regulatory factor expression (Peterson et al., 2008).
Similar results were obtained in transgenic (ob/ob, db/db) models
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of T2DM. Specifically, impaired SC proliferation and activation
were observed and were reflected in measurable impairments of
muscle regeneration (Nguyen et al., 2011). A critical, but as of
yet unanswered, question is the role of altered leptin signaling in
mediating changes to SCs in these animal models. Interestingly,
these authors found no difference in SC function or regenerative
capacity in HFF mice (Nguyen et al., 2011).
In addition to altered myogenic potential, SCs derived from
T2DM patients were found to retain a “diabetic phenotype”
upon isolation and culturing. These T2DM-derived SCs displayed
reduced lipid oxidation (Gaster et al., 2004), increased secre-
tion of inflammatory markers leading to altered cell signaling
(Green et al., 2011), impaired glucose transport (Gaster et al.,
2002), and insulin-resistance (Scarda et al., 2010). These mod-
ifications were based on T2DM-induced epigenetic changes to
muscle cell gene programming, modifying protein expression of
factors essential to myogenesis, thereby permanently affecting
muscle SCs (Broholm et al., 2012). Taken together, these find-
ings suggest that the degree of T2DM disease severity (i.e., diet
vs. genetic model) will differentially influence SC function. A
more severe T2DM phenotype, as is found in genetic models of
T2DM, results in impairments to the early stages of myogenesis
(proliferation, activation), while the HFFmodels will alter the dif-
ferentiation potential of the SCs. Finally, long-term exposure to
T2DM may promote detrimental epigenetic changes to SCs that
will inevitably affect their functionality, and ultimately, overall
skeletal muscle health.
MECHANISMS FOR ALTERED SATELLITE CELL FUNCTION IN
DIABETES MELLITUS
The literature is clear that the uncontrolled diabetic environ-
ment is unfavorable for skeletal muscle growth and regeneration
(Vignaud et al., 2007; Peterson et al., 2008; Krause et al., 2011;
Nguyen et al., 2011). However, the molecular processes governing
changes to the SCs are far from elucidated.
Following a period of uncontrolled diabetes mellitus in
humans (i.e., pre-diagnosis), insulin administration is the thera-
peutic standard, and is well studied in terms of regulating muscle
protein turnover (Pain et al., 1983; Price et al., 1996; Charlton and
Nair, 1998; Lee et al., 2004). What remains less known is the effect
of insulin therapy on SCs. Insulin has been found to stimulate
both proliferation and differentiation of SCs, with such evidence
derived from a handful of in vitro studies (Ewton and Florini,
1981; Vandenburgh et al., 1991; Cassar-Malek et al., 1999). The
paucity of data available from human diabetic muscle exposed
to insulin treatment merits further consideration. In the absence
of insulin, or poorly managed diabetic states, there may be a
myriad of factors and processes stemming from the diabetic envi-
ronment that have the potential to influence SC activity. After
a review of many of these mechanisms, a select few are evident
in both T1DM and T2DM. The precise modifications to skeletal
muscle following diabetes onset is depicted along with the pre-
dicted mechanisms of action (Figure 1). These include, but are
not limited to: oxidative stress, chronic low-grade inflammation,
and impaired ECM remodeling. Though the impact of metabolic
diseases on the changing metabolic needs of the muscle satellite
cells as they move from quiescence through to differentiation is
certainly of note, it is beyond the scope of this mini-review. We
refer the readers to some excellent recent reviews (Fulco et al.,
2008; Ryall, 2013) on this topic.
OXIDATIVE STRESS
Oxidative stress is evident in both T1DM (Aragno et al., 2004)
and T2DM (Henriksen et al., 2010), and has been directly associ-
ated with elevated glucose concentrations (Bonnefont-Rousselot,
2002). Dysregulation of nitric oxide (NO) production also occurs,
as hyperglycemia promotes the formation of reactive nitrogen
species (RNS) to further exacerbate levels of oxidative stress
(Zou et al., 2002). A shift in pro-oxidant/antioxidant balance is
regarded in the pathogenesis of diabetes and its complications
(Evans et al., 2002). Although an emphasis of research relating
oxidative stress to skeletal muscle health has been on its mod-
ulation of protein turnover (Li et al., 1998; Zhou et al., 2001;
Aragno et al., 2004), it is speculated that the concomitant increase
in ROS and decrease in NO hinders satellite cell function. In
vitro work has found that acute treatment of human muscle SCs
with the ROS-inducing agent hydrogen peroxide (H2O2) led to
reduced cell viability, shortened lifespan, and decreased prolif-
erative capacity (Renault et al., 2002). In support of oxidative
stress impairing myogenesis, Aragno et al. (2004) found that in
response to muscle damage, the expression of critical myogenic
factors (MyoD, myogenin, and Jun D) was reduced in STZ-
diabetic rodents compared to non-diabetic rodents. Muscle crea-
tine kinase and myosin expression were also impaired, suggesting
that defects in the early phases of regeneration (i.e., satellite cell
functionality) led to a cascade of events to further hinder muscle
repair. It is interesting to note that oxidative stress has been impli-
cated in the adipogenic conversion of muscle SCs (Vettor et al.,
2009). Now whether this occurs within diabetic muscle has yet to
be defined, however, given that the demonstrated impairments in
myogenesis with diabetes appear to be linked to oxidative stress,
it is clear that this area requires further investigation.
CHRONIC LOW-GRADE INFLAMMATORY PROFILE (CLIP)
With diabetes progression, a multitude of pro-inflammatory fac-
tors are elevated, constituting a state of chronic low-grade inflam-
mation, or a chronic low-grade inflammatory profile (CLIP).
The presence of this condition is evident in all forms of dia-
betes mellitus (Llauradó et al., 2012; Osborn and Olefsky, 2012)
and is believed to occur as a result of the enhanced forma-
tion of advanced glycation end-products (AGEs; Tan et al., 2004;
Ramasamy et al., 2005; Yan et al., 2008). The factors associ-
ated with CLIP can collectively and/or independently influence
SC activity. While examination of each of these factors on SC
function is beyond the breadth of this review, it is important to
highlight a select few.
Chronic elevations of circulating Interleukin-6 (IL-6) are
observed in T1DM and T2DM (Pradhan et al., 2001; Reis et al.,
2012). While transient increases in IL-6 are associated with SC
proliferation (Toth et al., 2011), chronically elevated IL-6 is cor-
related with significant decrements in muscle health (e.g., cancer
cachexia; Roubenoff, 1997; McKay et al., 2013). Given the chronic
elevations in IL-6 with diabetes, it is reasonable to surmise that
impairments to SC functionality are occurring. Consistent with
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FIGURE 1 | Impact of Diabetes Mellitus on Skeletal Muscle Health.
While the etiology and progression for T1DM and T2DM development
are distinct, both diseases negatively influence skeletal muscle (referred
to as “Diabetic Muscle”) and their resident progenitor cell populations,
including satellite cells. Satellite cells are critical to muscle health, and
are affected by diabetes mellitus at varying stages of adult myogenesis.
As outlined in this review, and schematized here, chronic low grade
inflammation (also known as CLIP, or chronic low-grade inflammatory
profile), oxidative stress, and impaired extracellular matrix remodeling
are proposed to be common denominators for mechanisms underlying
impairments to muscle health and decreased satellite cell functionality
in diabetes mellitus.
this hypothesis, obese diabetic individuals displayed significant
impairments in IL-6 signaling within their skeletal muscle that
persisted within the satellite cells even upon removal from the
diabetic environment (Nielsen et al., 2012).
Akin to IL-6, tumor necrosis factor-α (TNF-α) functions as a
keymediator of the inflammatory process. Not only is TNF-α cor-
related with diabetes progression (Csizuadia et al., 2012; Swaroop
et al., 2012), it has also been found to alter insulin-mediated glu-
cose uptake in muscle cells in vitro (Yoon et al., 2011), and has
been implicated in the development of insulin resistance through
studies knocking out its respective receptors (Uysal et al., 1997;
Romanatto et al., 2009). With respect to SCs, TNF-α is thought
to exert its effects through stimulation of factors that promote
entry into the cell cycle (Li et al., 2003). In support of this, TNF-
α treated myoblasts displayed an increased proliferative capacity
while differentiation was hindered (Alter et al., 2008).
The presence of CLIP, as found in diabetes, will undoubtedly
alter skeletal muscle homeostasis. This emerging and exciting new
area of interest, though still in its infancy, presents an intriguing
avenue for further therapeutic investigations.
IMPAIRED EXTRACELLULAR MATRIX (ECM) REMODELING
Studies have found that central constituents of the plasminogen
system are required for normal growth and repair within a vari-
ety of tissues types, including skeletal muscle (Romer et al., 1996;
Lluís et al., 2001; Shimizu et al., 2001). Within muscle, inhibi-
tion of PAI-1 (a critical inhibitor of the plasminogen system) was
found to increase MyoD expression and accelerate muscle repair
(Koh et al., 2005). Of particular note, elevated ECM levels have
been demonstrated in a variety of diabetic tissues (Berria et al.,
2006; Krause et al., 2011). Excessive ECM levels are likely the
result of altered protein expression (Lecker et al., 2004), espe-
cially in regards to matrix metalloproteinases (Hopps and Caimi,
2012). The improper turnover of ECM proteins may also hinder
growth factor signaling, further impeding myogenesis (Gopinath
and Rando, 2008). While the aforementioned studies identify that
aspects of muscle health are clearly subject to modification with
diabetes mellitus, one must also account for diabetic-induced
changes to the environment in which the muscle SCs reside. The
adverse remodeling of the ECM in diabetic muscle, as evidenced
by increased collagen presence, will inevitably affect SC func-
tionality and its capacity to migrate within regenerating muscle
(Krause et al., 2013). These defects are also prevalent in senescent
skeletal muscle (Franceschi, 2007; Kurtz and Oh, 2012; Vasilaki
and Jackson, 2013). Thus, potential therapies to attenuate neg-
ative alterations to SC behavior with diabetes onset may also
function to mitigate sarcopenia.
SIGNIFICANCE AND CONCLUSIONS
Diabetes mellitus is a global health concern. While diabetes mel-
litus begins as a result of an impairment in insulin signaling
(deficiency/resistance), numerous other factors quickly become
altered making the pathogenesis of diabetic complications multi-
faceted. Here we provide an overview of the importance of the
muscle SC, the impact of T1DM and T2DM on this cell pop-
ulation, and potential “common” mechanisms for altered SC
function. Based on the limited number of studies to date, it is
evident that various stages of the myogenic process are affected
by diabetes mellitus and impairments to SC function are occur-
ring. Given the vital role of these cells in the lifelong main-
tenance of skeletal muscle, and the importance of a physically
and metabolically healthy skeletal muscle mass in attenuating
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the morbidity and mortality associated with diabetes mellitus, a
comprehensive understanding of SC in the diabetic environment
is of fundamental significance. Identifying the proponents that
attenuate normal SC function in diabetes mellitus will lead to
the development of therapies that restore SC activity in order to
sustain muscle health, and subsequently attenuate other diabetic
complications.
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